Tag: medical (page 1 of 34)

CBD Shown to be Effective for Treating Schizophrenia in Randomized Controlled Trial

Cannabidiol has been shown to have beneficial effects for the treatment of schizophrenia in a study conducted by a wide variety of organizations. This is promising for sufferers of the condition and good news for cannabis, which has received a lot of negative press and coverage regarding THC and its possible effects on schizophrenia.

The study is: “Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.”

The various organizations involved with the findings are:

The study, an “8-week, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial was conducted at 15 hospital sites in the U.K., Romania, and Poland” where patients were either given 1,000 mg/day of CBD orally in two doses, or a placebo.

The results were clear that CBD was effective in the “Positive and Negative Syndrome Scale” or PANSS score:

CBD Showing Positive PANSS Results

CBD Shows Positive PANSS Results

The changes over the course of the treatment also clearly showed improvements for those taking CBD over a placebo in their Clinical Global Impressions severity scores:

CBD Better than Placebo in Clinical Global Impressions Severity Scores at End of Treatment

CBD Better than Placebo in Clinical Global Impressions Severity Scores at End of Treatment

There have been a number of studies on cannabis and schizophrenia over the years, with much attention paid to the possibly exacerbating effects of THC on the condition. This study doesn’t provide guidance to start using cannabis as treatment for schizophrenia, but it does show promise for CBD as a treatment.

“This is, to our knowledge, the first placebo-controlled trial of CBD in schizophrenia. The data indicate that 6 weeks of treatment adjunctive to antipsychotic medication was associated with significant effects both on positive psychotic symptoms and on the treating clinicians’ impressions of improvement and illness severity. There were also improvements in cognitive performance and in the level of overall functioning, although these fell short of statistical significance.”

For the most up to date info on Cannabis Reports, follow us on Twitter, and like us on our Facebook page.

Jeff Sessions: “Healthy to Have Some More Competition” in Medical Cannabis Research Supply

Attorney General Jeff Sessions responded to “reports that DOJ and DEA are at odds on marijuana research, particularly when it comes to granting applications to grow marijuana for further research.” This concern came from Senator Hatch [R-UT] during an Oversight of the U.S. Department of Justice hearing.

Earlier in the year, the Drug Enforcement Administration opened up Applications To Become Registered Under the Controlled Substances Act To Manufacture Marijuana To Supply Researchers in the United States. The application itself consists of four pages and asks:

“Make checks payable to “Drug Enforcement Administration”.

Depending on the type of “Business Activity”, the fees range from $244 per year, to $3,047.

Fees for Business Types on Application

Screenshot from Application

You’ll be able to tick the box next to substances like Heroin, Mescaline, Peyote, or MDMA.

Screenshot of Substances from Application

Screenshot of Substances from Application

According to Sessions:

“I believe there are now 26 applications for approval of suppliers who would provide marijuana for medicinal research. Each one of those has to be supervised by the DEA and I have raised questions about how many and let’s be sure we’re doing this in the right way ’cause it costs a lot of money to supervise these events.”

Senator Hatch wasn’t just bringing this up out of nowhere. Alongside Senator Schatz [D-HI] he:

“introduced…the bipartisan Marijuana Effective Drug Studies Act of 2017 or the MEDS Act because I believe that scientists need to study the potential benefits and dangers of marijuana.”

The MEDS Act pushes for more research and production when it comes to medical cannabis and pushes for standards to be written for “good manufacturing practices.”

And while Sessions thinks “it’d be health to have some competition in this supply,” he’s quick to state:

“I’m sure we don’t need 26 new suppliers.”

For the most up to date info on Cannabis Reports, follow us on Twitter, and like us on our Facebook page.

Patients Choosing Cannabis Over Opioids During Self-Funded Study

Dr. James Feeney is doing something incredible for cannabis medicine. He hopes to end the opiate epidemic by bluntly showing the effectiveness of cannabis over pharmaceutical alternatives.

Dr. Feeney is a surgeon and Director of Trauma Services at St. Francis Hospital and Medical Center in Hartford Connecticut. With his research partner Dr. David Shapiro, they approached the St. Francis administration, including the legal team and the chief of surgery with a proposal to test cannabis in direct competition with opioids.

No one objected, despite St. Francis being a Catholic hospital.

St. Francis Hospital and Medical Center: Hartford, CT.

So they took the proposal to St. Francis Hospital’s parent company, Trinity Health. According to Feeney, Trinity Health was supportive, and even wondered why they were not already conducting cannabis exams. Feeney describes the overall feelings revealed by those conversations: “Anybody that takes even a cursory look at the medical literature understands that this could be used to replace opiate pain medication.”

Dr. James Feeney (source)

Feeney first began seriously considering cannabis for his patients after multiple patients refused opioids, and said they would just use cannabis instead. After hearing this anecdotal information first-hand, and witnessing the positive reactions, Dr. Feeney felt the need to conduct a study.

Due to the current climate for cannabis in traditional medicine, Feeney had to secure external funding for the study. He proposed that he and his partner examine the effects of cannabis on acute pain, because a substantial amount of information already pointed to the efficacy of cannabis for chronic pain (15 studies).

An important aspect of Feeney’s study is that medical cannabis is already legal in Connecticut, meaning he and St. Francis can refrain from prescribing or distributing the Schedule I substance. This allows the doctors to conduct research without having to jump through the hoops of establishing approval for clinical trials.

Patients who already have their cards can elect to take place in the study, which allows them to choose opioids or cannabis to control their acute pain.

So far, every participant has chosen cannabis. Of course, all of the patients in the study have an existing familiarity with cannabis, but the fact that they choose cannabis over opioids when doctors give them the option is incredibly positive, and may change medical opinions across the country if the trend persists.

TheCannabis Reports database currently hosts 812 studies for 166 different medical conditions. Check it out!

For the most up to date info on Cannabis Reports, follow us on Twitter, and like us on our Facebook page.

Older posts